XmAb 808
Alternative Names: B7-H3 x CD28 - Xencor; XmAb-808Latest Information Update: 06 Dec 2022
At a glance
- Originator Xencor
- Class Antineoplastics; Bispecific antibodies; Immunotherapies
- Mechanism of Action Antibody-dependent cell cytotoxicity; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase I Solid tumours
Most Recent Events
- 30 Nov 2022 Phase-I clinical trials in Solid tumours (Second-line therapy or greater, Late-stage disease, Metastatic disease, Combination therapy) in USA (IV) (NCT05585034)
- 11 Jan 2022 Xencor plans phase I trial in Solid tumours (Late-stage disease, Metastatic disease, Combination therapy) in November 2022
- 11 Jan 2022 Xencor announces intention to file an IND application in first half of 2022